186 related articles for article (PubMed ID: 20332473)
1. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma.
Kobayashi H; Tanaka Y; Shimmura H; Minato N; Tanabe K
Anticancer Res; 2010 Feb; 30(2):575-9. PubMed ID: 20332473
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
Kobayashi H; Tanaka Y; Yagi J; Minato N; Tanabe K
Cancer Immunol Immunother; 2011 Aug; 60(8):1075-84. PubMed ID: 21519826
[TBL] [Abstract][Full Text] [Related]
3. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.
Kobayashi H; Tanaka Y; Yagi J; Osaka Y; Nakazawa H; Uchiyama T; Minato N; Toma H
Cancer Immunol Immunother; 2007 Apr; 56(4):469-76. PubMed ID: 16850345
[TBL] [Abstract][Full Text] [Related]
4. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
5. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.
Weidmann E; Logan TF; Yasumura S; Kirkwood JM; Trucco M; Whiteside TL
Cancer Res; 1993 Oct; 53(20):4745-9. PubMed ID: 8402652
[TBL] [Abstract][Full Text] [Related]
6. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
Dieli F; Vermijlen D; Fulfaro F; Caccamo N; Meraviglia S; Cicero G; Roberts A; Buccheri S; D'Asaro M; Gebbia N; Salerno A; Eberl M; Hayday AC
Cancer Res; 2007 Aug; 67(15):7450-7. PubMed ID: 17671215
[TBL] [Abstract][Full Text] [Related]
7. Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: results from a prospective phase I/II trial.
Kunzmann V; Smetak M; Kimmel B; Weigang-Koehler K; Goebeler M; Birkmann J; Becker J; Schmidt-Wolf IG; Einsele H; Wilhelm M
J Immunother; 2012; 35(2):205-13. PubMed ID: 22306909
[TBL] [Abstract][Full Text] [Related]
8. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.
Sakamoto M; Nakajima J; Murakawa T; Fukami T; Yoshida Y; Murayama T; Takamoto S; Matsushita H; Kakimi K
J Immunother; 2011 Mar; 34(2):202-11. PubMed ID: 21304399
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of renal cell carcinoma with mediastinal lymph node metastasis by interleukin-2: a case report.
Tokunaga M; Masuda A; Mukai M; Nakamura H; Iwaki K; Terachi T
Tokai J Exp Clin Med; 2005 Jul; 30(2):111-5. PubMed ID: 16146201
[TBL] [Abstract][Full Text] [Related]
11. A new indicator of favorable prognosis in locally advanced renal cell carcinomas: gamma delta T-cells in peripheral blood.
Kobayashi H; Tanaka Y; Nakazawa H; Yagi J; Minato N; Tanabe K
Anticancer Res; 2011 Mar; 31(3):1027-31. PubMed ID: 21498733
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
[TBL] [Abstract][Full Text] [Related]
13. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.
Lang JM; Kaikobad MR; Wallace M; Staab MJ; Horvath DL; Wilding G; Liu G; Eickhoff JC; McNeel DG; Malkovsky M
Cancer Immunol Immunother; 2011 Oct; 60(10):1447-60. PubMed ID: 21647691
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.
Dokouhaki P; Han M; Joe B; Li M; Johnston MR; Tsao MS; Zhang L
Cancer Lett; 2010 Nov; 297(1):126-36. PubMed ID: 20537791
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
16. Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma.
Viey E; Laplace C; Escudier B
Expert Rev Anticancer Ther; 2005 Dec; 5(6):973-86. PubMed ID: 16336088
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
Thompson JA; Figlin RA; Sifri-Steele C; Berenson RJ; Frohlich MW
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3562-70. PubMed ID: 14506142
[TBL] [Abstract][Full Text] [Related]
19. Induction of cytotoxic T lymphocytes by CEA peptide-pulsed γδ T-cells isolated from patients with advanced cancer.
Yamasaki A; Onishi H; Morisaki T; Katano M
Anticancer Res; 2011 Jul; 31(7):2419-24. PubMed ID: 21873153
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.
Abe Y; Muto M; Nieda M; Nakagawa Y; Nicol A; Kaneko T; Goto S; Yokokawa K; Suzuki K
Exp Hematol; 2009 Aug; 37(8):956-68. PubMed ID: 19409955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]